z-logo
open-access-imgOpen Access
Identification of Neuregulin 1 as Predictor Outcome in Intracranial Astrocytoma
Author(s) -
Ridha Dharmajaya,
Abdurrahman Mouza
Publication year - 2021
Publication title -
open access macedonian journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.288
H-Index - 17
ISSN - 1857-9655
DOI - 10.3889/oamjms.2021.6338
Subject(s) - medicine , astrocytoma , neuregulin , neuregulin 1 , grading (engineering) , oncology , glioma , pathology , receptor , cancer research , biology , ecology
BACKGROUND: Astrocytoma is the most common primary brain tumor. The combination of adhesion molecules, proteases, and cytokines that regulate their expression likely underlies tumor progression. The cytokine of neuregulin 1 (NRG1) has a role in progression and invasion of tumor cells by activating signal after binding its receptor.AIM: To identification NRG1 expression with characteristic of intracranial astrocytoma patient is the purpose of this study.METHODS: This study uses analytic method with retrospective study. It analyzed the association between NRG1 expressions in astrocytoma patients. The study included 32 samples which were admitted to Haji Adam Malik Hospital Medan from September 2016 to August 2018.RESULTS: There was no significant association between NRG1 expression with age (p = 0.853) and gender (p = 0.565) of astrocytoma patients, while there was a significant association between NRG1 expression with cell proliferation (p = 0.00), WHO grading of astrocytoma (p = 0.00), and outcomes (p = 0.023). According to this study, the most common results are strong NRG1 expression has many cells proliferation in 10 (31.1%) patients, strong NRG1 expression with Grade IV astrocytoma found in 7 (21.9%) patients, and moderate NRG1 expression in live patient found in 7 (21.9%) patient.CONCLUSION: There is significant association between NRG1 expression and cell proliferation, WHO grading of astrocytoma, and outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here